Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 8/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 4/20 | 0.39 |
| ▸ | CDC25B | P30305 | 4/20 | 0.39 |
| ▸ | HMGCR | P04035 | 2/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487215 | 0.81 | EBP (0.55) | EBPPLA2G1BNPC1L1MEN1USP2 | |
| SCHEMBL18714859 | 0.81 | EBP (0.55) | EBPPLA2G1BNPC1L1MEN1USP2 | |
| SCHEMBL17487216 | 0.81 | EBP (0.55) | EBPPLA2G1BNPC1L1MEN1USP2 | |
| SCHEMBL18714858 | 0.81 | EBP (0.55) | EBPPLA2G1BNPC1L1MEN1USP2 | |
| SCHEMBL13185816 | 0.78 | EBP (0.55) | EBPPLA2G1BNPC1L1MEN1USP2 | |
| Pollinastanol SCHEMBL29423016 | 0.70 | ACLY (0.49) | EBPPLA2G1BNPC1L1MEN1USP2 | |
| SCHEMBL12806705 | 0.69 | POLA1 (0.74) | NPC1L1MEN1USP2LMNATP53 | |
| Cycloartanol SCHEMBL455049 | 0.68 | ACLY (0.67) | EBPCDC25ACDC25BHMGCR | |
| Cycloartanol SCHEMBL13324286 | 0.68 | ACLY (0.67) | EBPCDC25ACDC25BHMGCR | |
| Cycloartanol SCHEMBL13801860 | 0.68 | ACLY (0.67) | EBPCDC25ACDC25BHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317556-A1 | ATP SYNTHASE INHIBITORS AND STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AND AS POTENTIATORS FOR AMINOGLYCOSIDES AGAINST PATHOGENIC BACTERIA | SOCPRA SCIENCES ET GENIE S.E.C. | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317556-A1 | ATP SYNTHASE INHIBITORS AND STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AND AS POTENTIATORS FOR AMINOGLYCOSIDES AGAINST PATHOGENIC BACTERIA | ATP5ME, ATP5MG, ATP5F1A | EBP 859/4885PLA2G1B 2701/4885NPC1L1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.